567 related articles for article (PubMed ID: 33967780)
1. Resveratrol in Rodent Models of Parkinson's Disease: A Systematic Review of Experimental Studies.
Su CF; Jiang L; Zhang XW; Iyaswamy A; Li M
Front Pharmacol; 2021; 12():644219. PubMed ID: 33967780
[TBL] [Abstract][Full Text] [Related]
2. Neuroprotective effects of baicalein in animal models of Parkinson's disease: A systematic review of experimental studies.
Zhu Q; Zhuang X; Lu J
Phytomedicine; 2019 Mar; 55():302-309. PubMed ID: 30385133
[TBL] [Abstract][Full Text] [Related]
3. Resveratrol in experimental Alzheimer's disease models: A systematic review of preclinical studies.
Chen JY; Zhu Q; Zhang S; OuYang D; Lu JH
Pharmacol Res; 2019 Dec; 150():104476. PubMed ID: 31605783
[TBL] [Abstract][Full Text] [Related]
4. The Neuroprotective Effects of Cannabis-Derived Phytocannabinoids and Resveratrol in Parkinson's Disease: A Systematic Literature Review of Pre-Clinical Studies.
Prakash S; Carter WG
Brain Sci; 2021 Nov; 11(12):. PubMed ID: 34942876
[TBL] [Abstract][Full Text] [Related]
5. Plant-derived neuroprotective agents in Parkinson's disease.
Fu W; Zhuang W; Zhou S; Wang X
Am J Transl Res; 2015; 7(7):1189-202. PubMed ID: 26328004
[TBL] [Abstract][Full Text] [Related]
6. Neuroprotective effect of resveratrol on rotenone-treated C57BL/6 mice.
Zhao X; Wang J; Hu S; Wang R; Mao Y; Xie J
Neuroreport; 2017 Jun; 28(9):498-505. PubMed ID: 28471847
[TBL] [Abstract][Full Text] [Related]
7. Neuroprotective Effects of Resveratrol in In vivo and In vitro Experimental Models of Parkinson's Disease: a Systematic Review.
Dos Santos MG; Schimith LE; André-Miral C; Muccillo-Baisch AL; Arbo BD; Hort MA
Neurotox Res; 2022 Feb; 40(1):319-345. PubMed ID: 35013904
[TBL] [Abstract][Full Text] [Related]
8. The intranasal administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a new rodent model to test palliative and neuroprotective agents for Parkinson's disease.
Prediger RD; Aguiar AS; Moreira EL; Matheus FC; Castro AA; Walz R; De Bem AF; Latini A; Tasca CI; Farina M; Raisman-Vozari R
Curr Pharm Des; 2011; 17(5):489-507. PubMed ID: 21375482
[TBL] [Abstract][Full Text] [Related]
9. Anti-oxidant polydatin (piceid) protects against substantia nigral motor degeneration in multiple rodent models of Parkinson's disease.
Chen Y; Zhang DQ; Liao Z; Wang B; Gong S; Wang C; Zhang MZ; Wang GH; Cai H; Liao FF; Xu JP
Mol Neurodegener; 2015 Mar; 10():4. PubMed ID: 26013581
[TBL] [Abstract][Full Text] [Related]
10. alpha-Synuclein- and MPTP-generated rodent models of Parkinson's disease and the study of extracellular striatal dopamine dynamics: a microdialysis approach.
Bazzu G; Calia G; Puggioni G; Spissu Y; Rocchitta G; Debetto P; Grigoletto J; Zusso M; Migheli R; Serra PA; Desole MS; Miele E
CNS Neurol Disord Drug Targets; 2010 Aug; 9(4):482-90. PubMed ID: 20522009
[TBL] [Abstract][Full Text] [Related]
11. Classic toxin-induced animal models of Parkinson's disease: 6-OHDA and MPTP.
Schober A
Cell Tissue Res; 2004 Oct; 318(1):215-24. PubMed ID: 15503155
[TBL] [Abstract][Full Text] [Related]
12. Neuroprotective effect of resveratrol on 6-OHDA-induced Parkinson's disease in rats.
Jin F; Wu Q; Lu YF; Gong QH; Shi JS
Eur J Pharmacol; 2008 Dec; 600(1-3):78-82. PubMed ID: 18940189
[TBL] [Abstract][Full Text] [Related]
13. Oxidative Stress, Mitochondrial Dysfunction, and Neuroprotection of Polyphenols with Respect to Resveratrol in Parkinson's Disease.
Kung HC; Lin KJ; Kung CT; Lin TK
Biomedicines; 2021 Jul; 9(8):. PubMed ID: 34440122
[TBL] [Abstract][Full Text] [Related]
14. Neuroprotective properties of curcumin in toxin-base animal models of Parkinson's disease: a systematic experiment literatures review.
Wang XS; Zhang ZR; Zhang MM; Sun MX; Wang WW; Xie CL
BMC Complement Altern Med; 2017 Aug; 17(1):412. PubMed ID: 28818104
[TBL] [Abstract][Full Text] [Related]
15. Neurotoxin-based models of Parkinson's disease.
Bové J; Perier C
Neuroscience; 2012 Jun; 211():51-76. PubMed ID: 22108613
[TBL] [Abstract][Full Text] [Related]
16. Behavioral Tests in Neurotoxin-Induced Animal Models of Parkinson's Disease.
Prasad EM; Hung SY
Antioxidants (Basel); 2020 Oct; 9(10):. PubMed ID: 33081318
[TBL] [Abstract][Full Text] [Related]
17. Poloxamer 188-mediated anti-inflammatory effect rescues cognitive deficits in paraquat and maneb-induced mouse model of Parkinson's disease.
Ding W; Lin H; Hong X; Ji D; Wu F
Toxicology; 2020 Apr; 436():152437. PubMed ID: 32169474
[TBL] [Abstract][Full Text] [Related]
18. The retina as an early biomarker of neurodegeneration in a rotenone-induced model of Parkinson's disease: evidence for a neuroprotective effect of rosiglitazone in the eye and brain.
Normando EM; Davis BM; De Groef L; Nizari S; Turner LA; Ravindran N; Pahlitzsch M; Brenton J; Malaguarnera G; Guo L; Somavarapu S; Cordeiro MF
Acta Neuropathol Commun; 2016 Aug; 4(1):86. PubMed ID: 27535749
[TBL] [Abstract][Full Text] [Related]
19. Resveratrol alleviates motor and cognitive deficits and neuropathology in the A53T α-synuclein mouse model of Parkinson's disease.
Zhang LF; Yu XL; Ji M; Liu SY; Wu XL; Wang YJ; Liu RT
Food Funct; 2018 Dec; 9(12):6414-6426. PubMed ID: 30462117
[TBL] [Abstract][Full Text] [Related]
20. Exercise-Induced Neuroprotection and Recovery of Motor Function in Animal Models of Parkinson's Disease.
Palasz E; Niewiadomski W; Gasiorowska A; Wysocka A; Stepniewska A; Niewiadomska G
Front Neurol; 2019; 10():1143. PubMed ID: 31736859
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
